Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

ClinicalTrials.gov ID: NCT04204616

Public ClinicalTrials.gov record NCT04204616. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Study identification

NCT ID
NCT04204616
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Galderma R&D
Industry
Enrollment
500 participants

Conditions and interventions

Interventions

  • Nemolizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 10, 2021
Primary completion
Oct 25, 2026
Completion
Oct 25, 2026
Last update posted
Nov 11, 2025

2021 – 2026

United States locations

U.S. sites
57
U.S. states
24
U.S. cities
52
Facility City State ZIP Site status
Galderma Investigational Site Birmingham Alabama 35233
Galderma Investigational Site Birmingham Alabama 35244
Galderma Investigational Site Fountain Valley California 92708
Galderma Investigational Site Los Angeles California 90045
Galderma Investigational Site San Diego California 92123
Galderma Investigational Site San Diego California 92130
Galderma Investigational Site Santa Monica California 94404
Galderma Investigational Site Washington D.C. District of Columbia 20037
Galderma Investigational Site Aventura Florida 33180
Galderma Investigational Site Delray Beach Florida 33484
Galderma Investigational Site Hollywood Florida 33021
Galderma Investigational Site Largo Florida 33770
Galderma Investigational Site Miami Florida 33125
Galderma Investigational Site Miami Florida 33136
Galderma Investigational Site North Miami Beach Florida 33162
Galderma Investigational Site Ormond Beach Florida 32174
Galderma Investigational Site Pembroke Pines Florida 33028
Galderma Investigational Site Tampa Florida 33607
Galderma Investigational Galderma Investigational Site Columbus Georgia 31904
Galderma Investigational Site Macon Georgia 31217
Galderma Investigational Site Newnan Georgia 30263
Galderma Investigational Site Chicago Illinois 60602
Galderma Investigational Galderma Investigational Site Chicago Illinois 60613
Galderma I Galderma Investigational Site Lake Bluff Illinois 60044
Galderma Investigational Site Indianapolis Indiana 46250
Galderma Investigational Site Topeka Kansas 66614
Galderma Investigational Site Louisville Kentucky 40241
Galderma Investigational Site Baltimore Maryland 21231
Galderma Investigational Site Boston Massachusetts 02111
Galderma Investigational Site Ann Arbor Michigan 48109
Galderma Investigational Site Saint Joseph Michigan 49085
Galderma Investigational Site Saint Joseph Missouri 64506
Galderma Investigational Site St Louis Missouri 63110
Galderma Investigational Site Henderson Nevada 89052
Galderma Investigational Site New York New York 10021
Galderma Investigational Galderma Investigational Site New York New York 10065
Galderma Investigational Site High Point North Carolina 27262
Galderma Investigational Site Raleigh North Carolina 27617
Galderma Investigational Site Winston-Salem North Carolina 27104
Galderma Investigational Site Cincinnati Ohio 45627
Galderma Investigational Site Cleveland Ohio 44106
Galderma Investigational Site Dublin Ohio 43016
Galderma Investigational Site Philadelphia Pennsylvania 19103
Galderma Investigational Site Anderson South Carolina 29621
Galderma Investigational Site Knoxville Tennessee 37909
Galderma Investigational Site Murfreesboro Tennessee 37130
Galderma Investigational Galderma Investigational Site Austin Texas 78738
Galderma Investigational Site Dallas Texas 75230
Galderma Investigational Site Dripping Springs Texas 78620
Galderma Investigational Site Houston Texas 77401
Galderma Investigational Site Pflugerville Texas 78660
Galderma Investigational Site Webster Texas 77004
Galderma Investigational Site Salt Lake City Utah 84117
Galderma Investigational Galderma Investigational Site Springville Utah 84663
Galderma Investigational Site Fairfax Virginia 22031
Galderma Investigational Site Lynchburg Virginia 24501
Galderma Investigational Site Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 107 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04204616, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 11, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04204616 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →